About UsClinical DevelopmentPartnershipsPatients/ProvidersInvestorsPress and Media

Recent News

Stay Informed

Click to receive news alerts
Our Mission

  • To advance patient treatment in cancer
  • To apply new insights from molecular and cancer biology to understand how to improve the efficacy and safety of approved and developmental cancer therapies
  • To develop and commercialize a diverse, risk-sensitive portfolio of cancer drugs to address unmet medical needs

PICASSO Trial Program
A Phase II multicenter, parallel group, randomized study of palIfosfamide tris plus doxorubicin versus doxorubiCin in subjects with unresectAble or metastatic Soft tissue SarcOma

Now Enrolling: ZIOPHARM Oncology, Inc. has launched its global Phase 2 randomized controlled trial of palifosfamide in subjects with unresectable or metastatic soft-tissue sarcoma. (PICASSO).
Click here to learn more.



June 3, 2009

ZIOPHARM Oncology to Present at the 8th Annual Needham Life Sciences Conference More

June 1, 2009

ZIOPHARM Presents Positive Darinaparsin Clinical Data at ASCO's Prestigious Clinical Science Symposium More




Video Media Coverage

Businessweek article
July 23, 2007 issue More

Businessweek article
May 5, 2008 issue More

Forbes.com article
May 9, 2008 issue More

ZIO-101 listed as 100 Great Investigational Drugs by R&D Directions More

ZIO-201 listed as 100 Great Investigational Drugs by R&D Directions More

Webcast Events and Presentations

ZIOPHARM ONCOLOGY INC at the 8th Annual Needham Life Sciences Conference
June 11, 2009
Click Here for More Information

ZIOPHARM Oncology, Inc. 2009 Annual Shareholder Meeting
June 4, 2009
Click Here for More Information

©2008 ZIOPHARM Oncology, Inc. | Privacy Policy | Terms & Conditions